(Hedgeweek) August proved to be a strong month for hedge funds specialising in life sciences and biopharma stocks, with several firms reporting solid gains that helped many return to positive territory for the year, according to a report by Institutional investor.
Biopharma hedge funds maintain momentum in August
This entry was posted in Syndicated. Bookmark the permalink.
